Analysis of exposure-response of CI-945 in patients with epilepsy: Application of novel mixed hidden Markov modeling methodology

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 3, 2012, Pages 263-271

  Delattre, Maud ^a   Savic, Radojka M ^b,c   Miller, Raymond ^d,e   Karlsson, Mats O ^f   Lavielle, Marc ^a  

^a Université de Paris Sud   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c University of California   (United States)

^d PFIZER INC   (United States)

^e DAIICHI SANKYO INC   (United States)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

CI 945; Epilepsy; Maximum likelihood estimation; Mixed hidden Markov model; Monolix

Indexed keywords

GABAPENTIN; PLACEBO;

ARTICLE; DISEASE ACTIVITY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RESPONSE; EPILEPSY; HIDDEN MARKOV MODEL; HUMAN; METHODOLOGY; MORBIDITY; MULTICENTER STUDY (TOPIC); POISSON DISTRIBUTION; PRIORITY JOURNAL; PROBABILITY;

ADOLESCENT; ADULT; AMINES; ANTICONVULSANTS; CHILD; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPILEPSY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; YOUNG ADULT;

EID: 84865504028     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9248-2     Document Type: Article

References (10)

1. Miller R et al (2003) Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures. Clin Pharmacol Ther 73(6):491-505
2. Snoeck E, Stockis A (2007) Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. Epilepsy Res 73(3):284-291
3. Trokoñiz IF, Plan E, Miller R, Karlsson MO (2009) Modelling overdispersion and Markovian features in count data. J Pharmacokinet Pharmacodyn 36(5):461-477
4. Durbin R, Eddy S, Krogh A, Mitchison G (1998) Biological sequences analysis. Cambridge University Press, Cambridge
5. Rabiner LR (1989) A tutorial on hidden Markov models and selected applications in speech recognition. Proc IEEE 77(2): 257-286
6. Haussler D, Krogh A, Mian I (1994) A hidden Markov model that finds genes in E. coli DNA. Nucleic Acids Res 22(22):4768-4778
7. Altman RM (2007) Mixed hidden Markov models: an extension of the hidden Markov model to the longitudinal data setting. J Am Stat Assoc 102(477):201-210
8. Rijmen F, IP EH, Rapp S, Shaw EG (2008) Qualitative longitudinal analysis of symptoms in patients with primary and metastatic brain tumours. J R Stat Soc Ser A Stat Soc 171(3):739-753
9. Maruotti A, Rydn T (2009) A semiparametric approach to hidden Markov models under longitudinal observations. Stat Comput 19:381-393
10. The Monolix software, Monolix Users Guide. http://software.monolix. org.